Tempus AI (TEM) Could Be 18% Below Fair Value As FDA Clearance Lands

Tempus AI (TEM) shares are drawing attention after the company received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-PH, its AI software for detecting pulmonary hypertension from standard ECGs.

The FDA news lands after a volatile stretch for Tempus AI, with the share price down 9.41% over the past day and 11.90% over the past week, yet still posting a 45.98% 30 day share price return and a 21.29% 90 day share price return. The 1 year total shareholder return is down 15.58%, suggesting momentum has picked up recently even as longer term holders remain under water at a latest share price of US$64.04.

Scan 39 healthcare AI stocks that, like Tempus AI after this latest FDA clearance, are working on AI tools aimed at real clinical problems rather than hype.

For Tempus AI, the sharp pullback after strong recent gains leaves a simple question: Are investors reassessing the business behind the new FDA clearance, or simply moving between excitement and caution as the valuation case comes under scrutiny next?

Most Popular Narrative: 15.4% Undervalued

Tempus AI's most followed valuation narrative pegs fair value at $75.68 compared with the latest close at $64.04, which implies a sizeable gap between price and that thesis.

Tempus AI isn't simply an AI software business (not another ChatBot). It is building a healthcare data platform where diagnostics, genomic testing, clinical data, and AI applications reinforce each other through a powerful network effect. The company generates revenue from multiple sources. Its Diagnostics business performs genomic testing for patients and providers, while its Data and Applications segment sells access to its massive de-identified datasets and AI-powered tools to pharmaceutical companies, researchers, and healthcare organizations. Every new test and partnership adds more data, making its AI models more valuable and creating opportunities to cross-sell additional products and services.

Read the complete narrative.

If this fair value for Tempus AI is right, it rests on a tight loop of growing data, richer software and improving profitability. Want to see how revenue growth, margins and future valuation multiples are stitched together to reach that $75.68 figure.

Result: Fair Value of $75.68 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Tempus AI still faces real pressure if its annual revenue growth of 17.67% slows materially, or if losses of US$254.43m persist longer than investors expect.

Find out about the key risks to this Tempus AI narrative.

Another View: SWS DCF Model Suggests Overvaluation

There is a very different message when you look at Tempus AI through the SWS DCF model. On this framework, the fair value comes out at $41.69 per share, while the current price is $64.04. That points to Tempus AI trading above this estimate rather than below it. For investors, the question is whether the data flywheel story justifies paying that kind of premium.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Tempus AI for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Tempus AI attracting both enthusiasm and caution, it may be useful to review the underlying data yourself and decide where you stand. To compare the potential benefits with the areas of concern, take a closer look at the 1 key reward and 2 important warning signs

Looking for more investment ideas beyond Tempus AI?

If you are weighing what to do next after Tempus AI, it makes sense to widen your watchlist and compare opportunities across different types of stocks.

Use these ideas as a starting point to apply the same disciplined thinking you brought to Tempus AI, and avoid missing opportunities that fit your approach.

• Target stability and capital preservation by reviewing a 75 resilient stocks with low risk scores that focuses on companies with more resilient profiles.
• Hunt for mispriced opportunities with a 45 high quality undervalued stocks that spotlights stocks where fundamentals and market prices appear out of sync.
• Strengthen your defensive side by scanning a list of solid balance sheet and fundamentals (52 results) that can help you focus on companies with sturdier financial foundations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com